Vancomycin is generally considered safe during pregnancy, but the drug behaves differently in a pregnant person’s body than it does in a non-pregnant adult. Pregnancy-driven increases in blood volume and kidney filtration expand the space the drug distributes into and speed its elimination, which can lower blood levels unless dosing is adjusted. Meanwhile, the placenta acts as a partial barrier, allowing some vancomycin through to the fetus but not in a simple or predictable way. Understanding these shifts matters because vancomycin is a front-line antibiotic for serious infections caused by resistant bacteria, and pregnant patients sometimes have no good alternative.
How Pregnancy Alters the Way Vancomycin Moves Through the Body
Several physiological changes during pregnancy conspire to alter how drugs are absorbed, distributed, and eliminated. Total body water increases substantially, blood volume rises, and cardiac output climbs. For a water-soluble (hydrophilic) drug like vancomycin, the most consequential shifts are an expanded volume of distribution and faster renal clearance. Both renal blood flow and the glomerular filtration rate rise by roughly 50%, sometimes as early as the second trimester, which can accelerate the elimination of renally cleared drugs by 20 to 65%.1Frontiers in Pharmacology. Physiologic and pharmacokinetic changes in pregnancy A larger volume of distribution means the same dose spreads into more fluid, potentially producing lower peak and trough concentrations than would be seen in a non-pregnant patient receiving the same amount.
A population pharmacokinetic study of vancomycin in pregnant women quantified these effects. In a typical pregnant patient, the central volume of distribution was about 67 liters, compared with roughly 38 liters in an equivalent non-pregnant patient. Clearance, however, was broadly similar between the two groups once body composition and creatinine clearance were accounted for, and the overall daily drug exposure (measured as the area under the concentration-time curve over 24 hours) came out nearly identical: around 223 in the pregnant group versus 226 in the non-pregnant group.2PubMed Central. Population Pharmacokinetics of Vancomycin in Pregnant Women That finding is somewhat reassuring: while the drug distributes into a much larger compartment, the body’s handling of vancomycin in pregnancy does not appear to produce dramatically different total exposure when dosing is appropriate.
The practical takeaway is that pregnant patients may need loading doses on the higher end of the range to achieve therapeutic concentrations quickly, because the drug is diluted across a larger fluid volume. But a comprehensive review of antibiotic pharmacokinetics in pregnancy concluded that, for vancomycin, no routine dose increase beyond the standard regimen appears necessary for most patients.3PubMed Central. The Pharmacokinetics and Target Attainment of Antimicrobial Drugs Throughout Pregnancy: Part III Non-penicillin and Non-cephalosporin Drugs That said, individual variation is wide, and monitoring drug levels remains important.
What Happens When Kidneys Go Into Overdrive
Some pregnant patients, particularly those in critical care, develop what clinicians call augmented renal clearance, where the kidneys filter blood much faster than expected for a given person’s size and age. This can push vancomycin out of the body so rapidly that standard doses fail to maintain adequate blood levels. In a study of critically ill obstetric patients, those with augmented renal clearance had lower initial trough concentrations compared with those without it (about 7.9 versus 9.5 milligrams per liter). Drug exposure dropped significantly, and clearance increased in the augmented group.4Frontiers in Pharmacology. A Regression Model to Predict Augmented Renal Clearance in Critically Ill Obstetric Patients and Effects on Vancomycin Treatment
For these patients, standard vancomycin dosing can result in concentrations that are too low to treat the infection effectively. The risk is that underdosing allows the bacteria to survive, prolongs the illness, and may promote resistance. Higher doses or more frequent administration may be needed, guided by measured drug levels rather than fixed protocols. This scenario underscores why therapeutic drug monitoring is not optional during pregnancy: the kidneys can surprise clinicians, and the only way to know what the drug is actually doing is to check.
How Much Vancomycin Crosses the Placenta
The placenta is not an impenetrable wall. Many drugs cross it to some degree, and the relevant question for vancomycin is how much gets through and how quickly. The answer depends on the experimental setup, and the two main approaches used to study this give somewhat different pictures.
In an ex vivo perfusion model, where a human placental lobule is kept alive in the lab and vancomycin is circulated through the maternal side, transfer to the fetal circuit was low. The fetal-side concentration reached only about 10% of the initial maternal concentration, and the placental tissue itself retained a significant amount of the drug.5PubMed Central. Transplacental transfer of vancomycin and telavancin A separate ex vivo perfusion study found even less transfer: at both peak and trough maternal concentrations, vancomycin was often undetectable in the fetal circuit, and no fetal accumulation occurred even when the system was left running for hours.6PubMed Central. Transplacental passage of vancomycin in the ex vivo human perfusion model
But studies done in living patients tell a different story. When vancomycin was given intravenously to non-infected pregnant women before cesarean delivery, cord blood vancomycin levels ranged from 2.8 to 9.4 micrograms per milliliter, and these concentrations showed a strong correlation with maternal serum levels over time. Cord blood concentrations approached maternal levels about four hours after the infusion ended.7Obstetrics & Gynecology. Transplacental Passage of Vancomycin in Noninfected Term Pregnant Women This suggests that in a real clinical scenario, where the drug circulates in the mother for hours, meaningful amounts do reach the fetus.
The difference between the lab and clinical findings likely reflects time. The perfusion experiments run for a limited window and simulate a single pass of blood through the placenta. In a living patient, vancomycin circulates repeatedly, and gradual, steady transfer across the placenta builds up fetal levels over hours. So while the placenta is clearly a barrier that slows vancomycin’s passage, it is not a block. Given enough time, the fetus is exposed.
Intrapartum Use and Cord Blood Levels
One of the most common reasons vancomycin is given during pregnancy is intrapartum prophylaxis against Group B Streptococcus (GBS) in patients who are allergic to penicillin and whose GBS isolate is resistant to clindamycin. The goal is to deliver enough drug to the fetus to prevent early-onset neonatal sepsis. A recent study of 26 neonates whose mothers received vancomycin during labor found that the vast majority, about 92%, had cord blood vancomycin levels above the breakpoint needed to inhibit GBS.8PubMed. Vancomycin Concentrations in Umbilical Cord Blood After Intrapartum Exposure This is encouraging because it means the drug does reach the newborn at concentrations likely to be bactericidal against GBS at the time of delivery.
That finding aligns with the in vivo placental transfer data described above, where cord blood levels tracked maternal levels with a few hours’ delay. If vancomycin is given early enough in labor, fetal concentrations have time to build to therapeutically useful levels. Timing of administration relative to delivery matters, and giving the drug too close to delivery may not allow enough time for adequate transfer.
Concerns About Preterm Neonates
Preterm infants pose a particular worry because their kidneys are immature and less able to clear drugs. A modeling study examined what happens to vancomycin in preterm neonates exposed through the placenta when mothers receive various intrapartum doses. As the maternal dose increased from 1,500 to 2,000 milligrams, the proportion of preterm neonates (born before 36 weeks) estimated to accumulate drug above the standard daily dose for neonates rose from about 23% to 34%. The risk was highest in the most premature infants (born before 34 or 35 weeks) and when birth occurred 12 to 18 hours or more after dosing.9PubMed Central. Sorting Out the Risks and Benefits of the #797 Recommended Intrapartum Vancomycin Dosing Approach
This does not necessarily mean these neonates will be harmed; it means they are getting more drug relative to their body size and kidney capacity than a term infant would. For a healthy term baby, the vancomycin that crosses the placenta is cleared without difficulty. For a 32-week premature infant with immature renal function, the same exposure could linger longer and reach higher levels in the blood and kidneys. Clinicians caring for anticipated preterm deliveries need to weigh the benefit of GBS prophylaxis against the potential for excessive neonatal drug accumulation, particularly when higher maternal doses are used.
Does Vancomycin Harm the Fetus?
The most feared potential toxicities of vancomycin are kidney damage (nephrotoxicity) and hearing damage (ototoxicity). Both have been studied in the context of pregnancy, though the human data are limited.
A study from 1989, which followed infants whose mothers received vancomycin during the second and third trimesters, found that renal function was normal in all infants and there was no evidence of sensorineural hearing loss or kidney toxicity.10American Journal of Obstetrics and Gynecology. Vancomycin during pregnancy: Does it cause hearing loss or nephrotoxicity in the infant? That study is often cited as the foundational human safety data, though it was small. No large controlled trial of vancomycin safety in human pregnancy has been done, because it would be unethical to randomly assign pregnant patients to receive a potentially harmful drug without clinical need.
Animal data are more nuanced. In a rat model, vancomycin accumulated in the kidneys of both the mother and the offspring across all three trimesters, and the amount increased as pregnancy progressed. Pup kidneys showed elevated levels of a biomarker for kidney injury when mothers received vancomycin in the first or second trimester, compared with control pups.11PubMed Central. Evaluation of Fetal and Maternal Vancomycin-Induced Kidney Injury during Pregnancy in a Rat Model The findings suggest that prolonged or repeated vancomycin exposure during pregnancy has the potential to cause subclinical kidney injury in the offspring, at least in rats.
Translating rat kidney data to human fetuses is not straightforward. Rats metabolize drugs differently, their placentas have a different structure, and the doses used in animal studies are often higher relative to body weight than what humans receive. Still, the rat data serve as a caution: vancomycin is not completely inert to the developing kidney, and longer courses or higher doses during pregnancy should not be given without a clear clinical reason. For short courses and intrapartum prophylaxis, the available human evidence is reassuring, but the gap in long-term follow-up data is real.
Effects on the Developing Microbiome
Beyond direct drug toxicity, there is a subtler concern: what vancomycin does to the bacterial communities that colonize the mother and, ultimately, the newborn. A mouse study found that giving vancomycin to pregnant dams disrupted their gut microbiota, and the offspring were born with lower microbial diversity and distinctly different bacterial communities compared with pups from untreated mothers. Interestingly, vancomycin itself was undetectable in the blood of both mothers and pups, meaning the effect on the offspring’s gut was not caused by the drug crossing into the baby’s blood. Instead, the disrupted maternal microbiome appeared to alter what bacteria were passed to the pups through breastmilk and other early exposures.12PubMed Central. Disruption of maternal gut microbiota during gestation alters offspring microbiota and immunity
The implications for human infants are still being studied, but the basic principle is plausible. The newborn gut is seeded in large part by maternal bacteria, and any antibiotic that disrupts the mother’s microbial ecosystem could change what the baby inherits. Altered early-life microbiota have been linked in other research to immune development and susceptibility to allergic and inflammatory conditions, though drawing a straight line from a course of intrapartum vancomycin to a specific childhood outcome remains speculative. This is an area where the science is still catching up to the concern.
Why Vancomycin Is Still Used Despite the Unknowns
Given the gaps in data, one might wonder why vancomycin is used in pregnancy at all. The answer is straightforward: the infections it treats, particularly methicillin-resistant Staphylococcus aureus (MRSA) bacteremia, endocarditis, or osteomyelitis, can be life-threatening to both mother and fetus. In the specific context of GBS prophylaxis, vancomycin is reserved for patients whose allergy profile and the resistance pattern of their GBS isolate leave no better option. Vancomycin sits alongside drugs like beta-lactams, clindamycin, and metronidazole in the category of antibiotics broadly considered safe and effective during pregnancy.13PubMed Central. A Review of Antibiotic Use in Pregnancy
The risk-benefit calculation is usually clear: untreated serious infections carry a far higher risk of fetal harm (preterm delivery, sepsis, death) than the theoretical risks of vancomycin exposure. That does not mean the drug should be prescribed casually. Every course during pregnancy should come with therapeutic drug monitoring to ensure levels stay in the effective range without climbing unnecessarily high, and the duration should be as short as clinically appropriate.
Monitoring Drug Levels in Pregnant Patients
Therapeutic drug monitoring for vancomycin has evolved in recent years. Current guidelines for the general population have moved toward targeting the area under the concentration-time curve (a measure of total drug exposure over time) rather than simply checking trough levels. In pregnant patients, this approach is arguably even more important, because the expanded volume of distribution can produce misleadingly low trough readings even when total exposure is adequate.
The population pharmacokinetic data confirm this: despite a nearly doubled central volume of distribution, overall daily exposure in pregnant women was comparable to that of non-pregnant adults.2PubMed Central. Population Pharmacokinetics of Vancomycin in Pregnant Women A clinician who only checks trough levels might react to a low number by escalating the dose, when in fact the patient is getting plenty of drug. This is one reason pharmacokinetic modeling and exposure-based monitoring are gaining ground in obstetric pharmacology.
For critically ill pregnant patients with augmented renal clearance, the challenge is reversed: the kidneys are eliminating vancomycin so quickly that both troughs and total exposure drop below effective levels.4Frontiers in Pharmacology. A Regression Model to Predict Augmented Renal Clearance in Critically Ill Obstetric Patients and Effects on Vancomycin Treatment In these cases, more aggressive dosing, sometimes with continuous infusion rather than intermittent boluses, may be needed. The common thread is that pregnancy introduces enough variability into vancomycin handling that fixed dosing protocols are less reliable than they are in the general population.
The Placenta as a Drug Reservoir
One finding that deserves attention is the observation that the placenta itself retains vancomycin. In the ex vivo perfusion study, the placental tissue held roughly 7.5 micrograms per gram of vancomycin by the end of the experiment.5PubMed Central. Transplacental transfer of vancomycin and telavancin This tissue retention may partially explain the discrepancy between the low fetal-circuit transfer seen in perfusion models and the higher cord blood levels seen in living patients. If the placenta acts as a slow-release reservoir, it could gradually leak vancomycin into the fetal circulation over time even after maternal blood levels have dropped.
Placental drug retention also raises questions about what happens to placental function. The placenta is not just a passive membrane; it is an active endocrine organ that produces hormones and modulates immune tolerance. Whether vancomycin accumulation in placental tissue affects any of these functions has not been studied in a meaningful way. This is a gap rather than a known risk, but it is one more reason to avoid unnecessary or prolonged vancomycin exposure during pregnancy when alternatives exist.
How First-Trimester Exposure Differs From Later Use
Most clinical data on vancomycin in pregnancy come from second- and third-trimester use, because that is when serious infections and GBS prophylaxis are most commonly encountered. First-trimester exposure is less well studied. The early human safety data specifically assessed second- and third-trimester exposure and found no hearing or kidney problems in infants.10American Journal of Obstetrics and Gynecology. Vancomycin during pregnancy: Does it cause hearing loss or nephrotoxicity in the infant? The rat study did find kidney biomarker elevation in pups exposed during the first trimester equivalent, but again, rodent findings do not translate directly to humans.11PubMed Central. Evaluation of Fetal and Maternal Vancomycin-Induced Kidney Injury during Pregnancy in a Rat Model
The first trimester is the period of organogenesis, when the fetus is most vulnerable to teratogenic effects. Vancomycin has not been classified as a known teratogen in humans, but the absence of evidence is not the same as evidence of absence. Pharmacokinetic changes are also less pronounced in the first trimester than later in pregnancy, since the major expansions of blood volume and kidney filtration ramp up mostly in the second trimester and beyond.1Frontiers in Pharmacology. Physiologic and pharmacokinetic changes in pregnancy If vancomycin is truly needed in early pregnancy, it can be given, but the uncertainty around first-trimester fetal effects makes careful consideration of alternatives and close monitoring all the more important.